Sanofi’s Larsen On Advances In Diabetes R&D And Payer Expectations
Dr Philip Larsen, Vice President, Research and Translational Medicine, R&D Diabetes Division, Sanofi tells Scrip in an interview which way potential gene therapy for diabetes may be headed and how the Sanofi-Evotec alliance is shaping. He also indicates that oral insulin, considered the holy grail of diabetes treatment, is a ‘really long journey’ with difficult prospects currently.
You may also be interested in...
USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.
Evotec's hybrid drug discovery model continues to attract pharma partners and generate internal assets using what its CEO calls a "diversified seed sowing" business approach.
Evotec has signed two more R&D deals with French major Sanofi that it hopes will help it move on from previous R&D disappointments.